Graphite Bio
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- $196M
Investors
- 14
About Graphite Bio
Based in California, US, and founded in 2020, Graphite Bio, Inc. is a gene-editing company that provides gene-replacement therapies intended for patients suffering from genetic diseases such as sickle cell disease (SCD) and severe combined immune deficiency (SCID). The company was co-founded by Matthew Porteus and Maria Grazia Roncarolo. Josh Lehrer as the CEO. In 2021, Graphite Bio, Inc. The company launched its IPO of 14 million shares for USD 17 per share. The company began trading on the Nasdaq Global Market under the ticker symbol, GRPH. Graphite’s pipeline of products consists of GPH101 – an HSC product candidate for therapy for sickle cell disease (SCD), GPH201 - hematopoietic stem cell treatment for patients with severe combined immune deficiency (SCID) with IL2RG deficiency, known as x-linked SCID (XSCID), and GPH301 – treatment for Gaucher disease. The company generates revenue by selling developed therapies to pharmaceutical companies. A pharmaceutical company will approach Graphite Bio, Inc. to observe therapies under clinical trial. Once therapy was approved, the company will be paid for its developed cure of a certain genetic disease, depending on the agreement. plans to use the investment for product development and expansion. Graphite Bio intends to develop GPH301 for the treatment of both Type 1 and Type 3 Gaucher disease and explore targeted conditioning regimens.
Who invested in Graphite Bio
14 investors across 2 rounds
See all investors in Graphite Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Graphite Bio
Who invested in Graphite Bio?
Graphite Bio has 14 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Graphite Bio raised?
Graphite Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Graphite Bio last raise money?
Graphite Bio's most recent round on record is a Series B, in Mar 2021.
What does Graphite Bio do?
Based in California, US, and founded in 2020, Graphite Bio, Inc.
Where is Graphite Bio headquartered?
Graphite Bio is headquartered in San Francisco, US.
Which VCs invest in companies like Graphite Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Graphite Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Graphite Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.